{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:16:57Z","timestamp":1792819017551,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01271-3","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T08:27:06Z","timestamp":1744705626000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Outcomes of patients with relapsed\/refractory lymphoplasmacytic lymphoma\/waldenstr\u00f6m macroglobulinemia treated with venetoclax: a multicenter retrospective analysis"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6355-3671","authenticated-orcid":false,"given":"Y.","family":"Sawalha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0075-6735","authenticated-orcid":false,"given":"S.","family":"Sarosiek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. L.","family":"Welkie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Seif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Thapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-8453","authenticated-orcid":false,"given":"S.","family":"Zanwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Cahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Treitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pongas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7261-1335","authenticated-orcid":false,"given":"A.","family":"Major","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2719-0580","authenticated-orcid":false,"given":"P. A.","family":"Riedell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5099-9156","authenticated-orcid":false,"given":"M. L.","family":"Palomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-364X","authenticated-orcid":false,"given":"P.","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Grajales-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. H.","family":"Shain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. K.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-7532","authenticated-orcid":false,"given":"J. J.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"1271_CR1","doi-asserted-by":"publisher","first-page":"e827","DOI":"10.1016\/S2352-3026(20)30224-6","volume":"7","author":"JJ Castillo","year":"2020","unstructured":"Castillo JJ, Advani RH, Branagan AR, Buske C, Dimopoulos MA, D'Sa S, et al. Review consensus treatment recommendations from the tenth international workshop for Waldenstr\u00f6m Macroglobulinaemia. Lancet Haematol. 2020;7:e827\u201337. https:\/\/doi.org\/10.1016\/S2352-3026(20)30224-6","journal-title":"Lancet Haematol"},{"key":"1271_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/bjh.13278","volume":"170","author":"Y Cao","year":"2015","unstructured":"Cao Y, Yang G, Hunter ZR, Liu X, Xu L, Chen J, et al. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4Wild-type and CXCR4WHIM mutated Waldenstrom macroglobulinaemia cells. Br J Haematol. 2015;170:134\u20138. https:\/\/doi.org\/10.1111\/bjh.13278","journal-title":"Br J Haematol"},{"key":"1271_CR3","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory Non-Hodgkin Lymphoma. J Clin Oncol. 2017;35:826\u201333. https:\/\/doi.org\/10.1200\/JCO.2016.70.4320","journal-title":"J Clin Oncol"},{"key":"1271_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.21.01194","volume":"40","author":"JJ Castillo","year":"2022","unstructured":"Castillo JJ, Allan JN, Siddiqi T, Advani RH, Meid K, Leventoff C, et al. Venetoclax in previously treated waldenstr\u00f6m macroglobulinemia. J Clin Oncol. 2022;40:63\u201371. https:\/\/doi.org\/10.1200\/JCO.21.01194","journal-title":"J Clin Oncol"},{"key":"1271_CR5","doi-asserted-by":"publisher","first-page":"e240001","DOI":"10.6004\/jnccn.2024.0001","volume":"22","author":"SK Kumar","year":"2024","unstructured":"Kumar SK, Callander NS, Adekola K, Anderson LD Jr, Baljevic M, Baz R, et al. Waldenstr\u00f6m Macroglobulinemia\/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22:e240001. https:\/\/doi.org\/10.6004\/jnccn.2024.0001","journal-title":"J Natl Compr Canc Netw"},{"key":"1271_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.seminhematol.2023.03.009","volume":"60","author":"SP Treon","year":"2023","unstructured":"Treon SP, Tedeschi A, San-Miguel J, Garcia-Sanz R, Anderson KC, Kimby E, et al. Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom\u2019s macroglobulinemia on diagnostic and response criteria. Semin Hematol. 2023;60:97\u2013106. https:\/\/doi.org\/10.1053\/j.seminhematol.2023.03.009","journal-title":"Semin Hematol"},{"key":"1271_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","volume":"127","author":"MS Cairo","year":"2004","unstructured":"Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127:3\u201311. https:\/\/doi.org\/10.1111\/j.1365-2141.2004.05094.x","journal-title":"Br J Haematol"},{"key":"1271_CR8","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/ajh.21788","volume":"85","author":"IM Ghobrial","year":"2010","unstructured":"Ghobrial IM, Xie W, Padmanabhan S, Badros A, Rourke M, Leduc R, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstr\u00f6m Macroglobulinemia. Am J Hematol. 2010;85:670\u20134. https:\/\/doi.org\/10.1002\/ajh.21788","journal-title":"Am J Hematol"},{"key":"1271_CR9","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1182\/bloodadvances.2020001963","volume":"4","author":"JJ Castillo","year":"2020","unstructured":"Castillo JJ, Meid K, Flynn CA, Chen J, Demos MG, Guerrera ML, et al. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstr\u00f6m macroglobulinemia: long-term follow-up. Blood Adv. 2020;4:3952\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2020001963","journal-title":"Blood Adv"},{"key":"1271_CR10","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1200\/JCO.2006.07.8659","volume":"25","author":"CI Chen","year":"2007","unstructured":"Chen CI, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, et al. Bortezomib is active in patients with untreated or relapsed Waldenstr\u00f6m\u2019s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1570\u20135. https:\/\/doi.org\/10.1200\/JCO.2006.07.8659","journal-title":"J Clin Oncol"},{"key":"1271_CR11","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1158\/1078-0432.CCR-06-2511","volume":"13","author":"SP Treon","year":"2007","unstructured":"Treon SP, Hunter ZR, Matous J, Joyce RM, Mannion B, Advani R, et al. Multicenter clinical trial of bortezomib in relapsed\/refractory Waldenstrom\u2019s macroglobulinemia: results of WMCTG trial 03-248. Clin Cancer Res. 2007;13:3320\u20135. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2511","journal-title":"Clin Cancer Res"},{"key":"1271_CR12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1182\/blood-2014-03-566273","volume":"124","author":"SP Treon","year":"2014","unstructured":"Treon SP, Tripsas CK, Meid K, Kanan S, Sheehy P, Chuma S, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstr\u00f6m\u2019s macroglobulinemia. Blood. 2014;124:503\u201310. https:\/\/doi.org\/10.1182\/blood-2014-03-566273","journal-title":"Blood"},{"key":"1271_CR13","doi-asserted-by":"publisher","first-page":"e852670f","DOI":"10.1097\/01.HS9.0000971328.85267.0f","volume":"7","author":"L Scarf\u00f2","year":"2023","unstructured":"Scarf\u00f2 L, Patel MR, Eyre TA, Jurczak W, Lewis D, Gastinne T, et al. P1108: efficacy Of Pirtobrutinib, a highly selective, non-covalent (Reversible) Btk inhibitor in relapsed\/Refractory Waldenstr\u00f6m Macroglobulinemia: results from The Phase 1\/2 Bruin Study. HemaSphere. 2023;7:e852670f. https:\/\/doi.org\/10.1097\/01.HS9.0000971328.85267.0f","journal-title":"HemaSphere"},{"key":"1271_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.40","volume":"7","author":"A Paulus","year":"2017","unstructured":"Paulus A, Akhtar S, Yousaf H, Manna A, Paulus SM, Bashir Y, et al. Waldenstrom macroglobulinemia cells devoid of BTK C481S or CXCR4 WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J. 2017;7:565. https:\/\/doi.org\/10.1038\/bcj.2017.40","journal-title":"Blood Cancer J"},{"key":"1271_CR15","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1182\/blood.2023022420","volume":"143","author":"JJ Castillo","year":"2024","unstructured":"Castillo JJ, Branagan AR, Sermer D, Flynn CA, Meid K, Little M, et al. Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-na\u00efve Waldenstr\u00f6m macroglobulinemia. Blood. 2024;143:582\u201391. https:\/\/doi.org\/10.1182\/blood.2023022420","journal-title":"Blood"},{"key":"1271_CR16","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1182\/blood-2024-198297","volume":"144","author":"JJ Castillo","year":"2024","unstructured":"Castillo JJ, Sarosiek SR, Branagan AR, von Keudell G, Flynn CA, Budano NS, et al. A phase II Study of pirtobrutinib and venetoclax in previously treated patients with waldenstr\u00f6m macroglobulinemia: an interim analysis. Blood. 2024;144:3011. https:\/\/doi.org\/10.1182\/blood-2024-198297","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01271-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01271-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01271-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T08:27:07Z","timestamp":1744705627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01271-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1271"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01271-3","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"31 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.G.C. reports honoraria from Janssen, Sanofi, Cellectar, Amgen, Bristol Myers Squibb, and Pfizer. A.W. has consulted for BeiGene, BTG Pharmaceuticals, AstraZeneca, and ADC Therapeutics. G.P. is a shareholder of Crispr Therapeutics and equity holder of Mevox Ltd and reports consultancy with ADC Therapeutics. J.J.C. received research funding from Abbvie, AstraZeneca, Beigene, Cellectar, Loxo, and Pharmacyclics, and consulting fees from Abbvie, AstraZeneca, Beigene, Cellectar, Janssen, Loxo, Mustang Bio, Nurix, and Pharmacyclics. K.H.S. reports honoraria from Amgen, Bristol Myers Squibb, Janssen, Adaptive, Sanofi, Regeneron, and Takeda, and research funding to the institution from AbbVie and Karyopharm, outside the submitted work. PAR reports serving as a consultant and\/or advisory board member for AbbVie, Novartis, BMS, ADC Therapeutics, Kite\/Gilead, Pfizer, CVS Caremark, Genmab, BeiGene, Janssen, Pharmacyclics, and Genentech\/Roche. Honoraria from Adaptive Biotechnologies. Research support from BMS, Kite Pharma, Novartis, CRISPR Therapeutics, Calibr, Xencor, Fate Therapeutics, AstraZeneca, Genentech\/Roche, Cellectis, Cargo Therapeutics, and Tessa Therapeutics. P.K. is the principal investigator of trials for which Mayo Clinic has received research funding from Amgen, Regeneron, Bristol Myers Squibb, Loxo Pharmaceuticals, Ichnos, Karyopharm, Sanofi, AbbVie and GlaxoSmithKline. Prashant Kapoor has received honorarium from Keosys and served on the Advisory Boards of BeiGene, Mustang Bio, Janssen, Pharmacyclics, X4 Pharmaceuticals, Kite Pharma, Oncopeptides, Ascentage, Angitia Bio, GlaxoSmithKline, Sanofi and AbbVie. SS received research funds or honoraria from Beigene, Cellectar, and ADC Therapeutics. ST received research funding from Ascentage Pharma, BMS, Genentech, Cellectar Biosciences, and Abbvie and has consulted for Cellectar Biosciences. YS received research funding from BeiGene, Genmab, and AbbVie and has consulted for ADC, Genmab, and Genentech.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}